×
About 52,170 results

ALLMedicine™ Bipolar Disorder Center

Research & Reviews  23,995 results

GRK3 deficiency elicits brain immune activation and psychosis.
https://doi.org/10.1038/s41380-021-01106-0 10.1016/j.pharmthera.2011.08.001 10.1042/BCJ20170093 10.1126/science.1118890 10.1523/JNEUROSCI.12-10-04045.1992 10.1016/S0006-8993(01)03046-3 10.1097/YPG.0b013e3280ae6c3d 10.1523/JNEUROSCI.5104-08.2009 10.1016/j.biopsych.2014.01.021 10.1016/j.bbr.2017.01.032 10.1038/mp.2009.52 10.1503/jpn.100080 10.1038/mp.2012.110 10.1038/s41380-019-0479-0 10.1038/s41582-019-0174-4 10.1176/appi.ajp.2018.17121311 10.1016/j.jpsychires.2012.12.001 10.1038/mp.2015.186 10.1038/mp.2016.90 10.1038/ng.2805 10.1176/appi.ajp.2013.12101298 10.1189/jlb.0213097 10.1016/bs.ai.2017.05.003 10.1016/j.nbd.2011.07.009 10.1038/sj.mp.4001268 10.1016/j.jpsychires.2009.08.010 10.1016/j.biopsych.2007.12.017 10.1016/j.bbi.2013.10.010 10.1017/S1461145708009383 10.1007/s11064-016-1939-4 10.1016/j.pbb.2007.01.018 10.1016/j.neuropharm.2018.06.003 10.7717/peerj.453 10.3389/fnbeh.2016.00046 10.1021/acs.jproteome.6b00830 10.1038/mp.2012.73 10.1111/bdi.12009 10.1007/s00213-001-0979-9 10.1007/7854_2011_195 10.1016/j.neuron.2006.09.023 10.1093/schbul/sbp132 10.1016/S0896-6273(03)00192-2 10.1016/j.phrs.2016.05.010 10.1016/S0166-2236(97)01139-9 10.1093/cercor/bhp202 10.1038/s41593-018-0334-7 10.1016/j.neuropharm.2016.05.020 10.1016/j.nbd.2003.12.015 10.1016/j.biopsych.2004.06.006 10.1111/j.1748-1716.1977.tb10404.x 10.1152/ajpcell.00315.2004 10.3389/fphar.2017.00123 10.1038/nrn3257 10.3389/fphar.2018.00052 10.1002/glia.23716 10.1038/nature21029 10.1016/j.neuron.2016.11.030 10.1038/srep17486 10.3389/fnins.2015.00148 10.1016/j.biopsych.2016.12.011 10.1016/j.bbr.2006.03.006 10.1038/sj.npp.1300188 10.1007/BF03033576 10.1016/j.tics.2011.11.015 10.1038/s41398-017-0071-9 10.1016/S0006-3223(99)00067-0 10.1073/pnas.93.17.9235 10.1073/pnas.94.6.2569 10.1016/S0304-3940(01)02242-X 10.1016/j.physbeh.2007.05.025 10.4137/IJTR.S4260 10.1016/S0006-3223(01)01078-2
Molecular Psychiatry; Sellgren CM, Imbeault S et. al.

May 12th, 2021 - The G protein-coupled receptor kinase (GRK) family member protein GRK3 has been linked to the pathophysiology of schizophrenia and bipolar disorder. Expression, as well as protein levels, of GRK3 are reduced in post-mortem prefrontal cortex of sch...

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a ne...
https://doi.org/10.1186/s12888-021-03220-3 10.1176/appi.books.9780890425596 10.1001/archpsyc.64.5.543 10.1001/archgenpsychiatry.2011.12 10.1016/j.jad.2017.09.011 10.1001/archpsyc.59.6.530 10.1111/j.1399-5618.2007.00467.x 10.1111/j.1399-5618.2008.00581.x 10.1176/ajp.2006.163.9.1561 10.1016/S0165-1781(97)00109-1 10.1016/S2215-0366(16)30264-4 10.1176/appi.ajp.2013.13020185 10.1017/S1461145709990344 10.1055/s-0033-1363258 10.1097/JCP.0b013e3181f15849 10.1080/15622975.2017.1285050 10.1111/acps.12343 10.1136/bmj.n71 10.1177/0272989X13487604 10.1016/j.jval.2011.01.011 10.1016/j.jval.2011.04.002 10.1016/j.jclinepi.2010.03.016 10.1186/s12916-017-0875-8 10.1016/j.jclinepi.2017.10.005 10.1136/bmj.g5630 10.1136/bmj.l4898 10.1016/j.jclinepi.2014.08.012 10.1176/appi.ajp.2015.15020164 10.1176/appi.ajp.2018.18070824 10.1111/bdi.12852 10.1097/YIC.0000000000000307 10.1007/s00213-016-4215-z 10.1176/appi.ajp.162.7.1351 10.1176/appi.ajp.2013.13070984 10.1097/JCP.0b013e31825ccde5 10.4088/JCP.08m04942gre 10.1016/j.jad.2014.07.007 10.1097/jcp.0b013e3181618eb4 10.1097/01.jcp.0000248603.76231.b7 10.1192/bjp.bp.112.108357 10.1001/archpsyc.60.11.1079 10.1007/s00213-014-3453-1 10.4088/JCP.08m04995gre 10.1093/ijnp/pyw100 10.1177/0269881116636545 10.1111/bdi.12609 10.1176/appi.ajp.2014.13111501 10.2147/NDT.S39227 10.1192/bjp.2019.16
BMC Psychiatry; Kadakia A, Dembek C et. al.

May 12th, 2021 - While clinical trial evidence has firmly established the efficacy of several atypical antipsychotics (AAPs) for treating bipolar depression, no randomized controlled trials (RCT's) comparing AAPs have been conducted. This Bayesian network meta-ana...

Impact of High-Deductible Health Plans on Medication Use Among Individuals With Bipolar...
https://doi.org/10.1176/appi.ps.202000362
Psychiatric Services (Washington, D.C.); Lu CY, Busch AB et. al.

May 11th, 2021 - High-deductible health plans (HDHPs) require substantial out-of-pocket spending for most services, although medications may be subject to traditional copayment arrangements. This study examined effects of HDHPs on medication out-of-pocket spending...

Editorial: The Early Phenotype of Bipolar Disorder?
https://doi.org/10.1016/j.jaac.2021.04.016
Journal of the American Academy of Child and Adolescent P... Mesman E

May 10th, 2021 - Editorial: The Early Phenotype of Bipolar Disorder?|2021|Mesman E,|

see more →

Guidelines  65 results

Nightmares in Patients with Major Depressive Disorder, Bipolar Disorder, and Psychotic Disorders: A Systematic Review
https://pubmed.ncbi.nlm.nih.gov/33317105/
Journal of Clinical Medicine; Akkaoui MA

Dec 8th, 2020 - Chronic nightmares are very common in psychiatric disorders, affecting up to 70% of patients with personality or post-traumatic stress disorders. In other psychiatric disorders, the relationships with nightmares are poorly known. This review aimed...

Allergan and Gedeon Richter Receive U.S. FDA Approval For Expanded Use of VRAYLAR® (cariprazine) in the Treatment of Bipolar Depression
https://www.allergan.com/news/news/thomson-reuters/allergan-and-gedeon-richter-receive-u-s-fda-approv.aspx

May 27th, 2019 - Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for VRAYLAR® (cariprazine) for expanded use to treat depressive episodes ass...

EPA guidance on physical activity as a treatment for severe mental illness: a meta-revi...
https://doi.org/10.1016/j.eurpsy.2018.07.004
European Psychiatry : the Journal of the Association of E... Stubbs B, Vancampfort D et. al.

Sep 27th, 2018 - Physical activity (PA) may be therapeutic for people with severe mental illness (SMI) who generally have low PA and experience numerous life style-related medical complications. We conducted a meta-review of PA interventions and their impact on he...

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder
https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.12609
Yatham,L.,et al

Apr 20th, 2018 - The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously pub-lished treatment guidelines for bipolar disorder in 2005, along with international com-mentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were...

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947163
Bipolar Disorders; Yatham LN, Kennedy SH et. al.

Mar 14th, 2018 - The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were p...

see more →

Drugs  959 results see all →

Clinicaltrials.gov  25,691 results

GRK3 deficiency elicits brain immune activation and psychosis.
https://doi.org/10.1038/s41380-021-01106-0 10.1016/j.pharmthera.2011.08.001 10.1042/BCJ20170093 10.1126/science.1118890 10.1523/JNEUROSCI.12-10-04045.1992 10.1016/S0006-8993(01)03046-3 10.1097/YPG.0b013e3280ae6c3d 10.1523/JNEUROSCI.5104-08.2009 10.1016/j.biopsych.2014.01.021 10.1016/j.bbr.2017.01.032 10.1038/mp.2009.52 10.1503/jpn.100080 10.1038/mp.2012.110 10.1038/s41380-019-0479-0 10.1038/s41582-019-0174-4 10.1176/appi.ajp.2018.17121311 10.1016/j.jpsychires.2012.12.001 10.1038/mp.2015.186 10.1038/mp.2016.90 10.1038/ng.2805 10.1176/appi.ajp.2013.12101298 10.1189/jlb.0213097 10.1016/bs.ai.2017.05.003 10.1016/j.nbd.2011.07.009 10.1038/sj.mp.4001268 10.1016/j.jpsychires.2009.08.010 10.1016/j.biopsych.2007.12.017 10.1016/j.bbi.2013.10.010 10.1017/S1461145708009383 10.1007/s11064-016-1939-4 10.1016/j.pbb.2007.01.018 10.1016/j.neuropharm.2018.06.003 10.7717/peerj.453 10.3389/fnbeh.2016.00046 10.1021/acs.jproteome.6b00830 10.1038/mp.2012.73 10.1111/bdi.12009 10.1007/s00213-001-0979-9 10.1007/7854_2011_195 10.1016/j.neuron.2006.09.023 10.1093/schbul/sbp132 10.1016/S0896-6273(03)00192-2 10.1016/j.phrs.2016.05.010 10.1016/S0166-2236(97)01139-9 10.1093/cercor/bhp202 10.1038/s41593-018-0334-7 10.1016/j.neuropharm.2016.05.020 10.1016/j.nbd.2003.12.015 10.1016/j.biopsych.2004.06.006 10.1111/j.1748-1716.1977.tb10404.x 10.1152/ajpcell.00315.2004 10.3389/fphar.2017.00123 10.1038/nrn3257 10.3389/fphar.2018.00052 10.1002/glia.23716 10.1038/nature21029 10.1016/j.neuron.2016.11.030 10.1038/srep17486 10.3389/fnins.2015.00148 10.1016/j.biopsych.2016.12.011 10.1016/j.bbr.2006.03.006 10.1038/sj.npp.1300188 10.1007/BF03033576 10.1016/j.tics.2011.11.015 10.1038/s41398-017-0071-9 10.1016/S0006-3223(99)00067-0 10.1073/pnas.93.17.9235 10.1073/pnas.94.6.2569 10.1016/S0304-3940(01)02242-X 10.1016/j.physbeh.2007.05.025 10.4137/IJTR.S4260 10.1016/S0006-3223(01)01078-2
Molecular Psychiatry; Sellgren CM, Imbeault S et. al.

May 12th, 2021 - The G protein-coupled receptor kinase (GRK) family member protein GRK3 has been linked to the pathophysiology of schizophrenia and bipolar disorder. Expression, as well as protein levels, of GRK3 are reduced in post-mortem prefrontal cortex of sch...

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a ne...
https://doi.org/10.1186/s12888-021-03220-3 10.1176/appi.books.9780890425596 10.1001/archpsyc.64.5.543 10.1001/archgenpsychiatry.2011.12 10.1016/j.jad.2017.09.011 10.1001/archpsyc.59.6.530 10.1111/j.1399-5618.2007.00467.x 10.1111/j.1399-5618.2008.00581.x 10.1176/ajp.2006.163.9.1561 10.1016/S0165-1781(97)00109-1 10.1016/S2215-0366(16)30264-4 10.1176/appi.ajp.2013.13020185 10.1017/S1461145709990344 10.1055/s-0033-1363258 10.1097/JCP.0b013e3181f15849 10.1080/15622975.2017.1285050 10.1111/acps.12343 10.1136/bmj.n71 10.1177/0272989X13487604 10.1016/j.jval.2011.01.011 10.1016/j.jval.2011.04.002 10.1016/j.jclinepi.2010.03.016 10.1186/s12916-017-0875-8 10.1016/j.jclinepi.2017.10.005 10.1136/bmj.g5630 10.1136/bmj.l4898 10.1016/j.jclinepi.2014.08.012 10.1176/appi.ajp.2015.15020164 10.1176/appi.ajp.2018.18070824 10.1111/bdi.12852 10.1097/YIC.0000000000000307 10.1007/s00213-016-4215-z 10.1176/appi.ajp.162.7.1351 10.1176/appi.ajp.2013.13070984 10.1097/JCP.0b013e31825ccde5 10.4088/JCP.08m04942gre 10.1016/j.jad.2014.07.007 10.1097/jcp.0b013e3181618eb4 10.1097/01.jcp.0000248603.76231.b7 10.1192/bjp.bp.112.108357 10.1001/archpsyc.60.11.1079 10.1007/s00213-014-3453-1 10.4088/JCP.08m04995gre 10.1093/ijnp/pyw100 10.1177/0269881116636545 10.1111/bdi.12609 10.1176/appi.ajp.2014.13111501 10.2147/NDT.S39227 10.1192/bjp.2019.16
BMC Psychiatry; Kadakia A, Dembek C et. al.

May 12th, 2021 - While clinical trial evidence has firmly established the efficacy of several atypical antipsychotics (AAPs) for treating bipolar depression, no randomized controlled trials (RCT's) comparing AAPs have been conducted. This Bayesian network meta-ana...

Impact of High-Deductible Health Plans on Medication Use Among Individuals With Bipolar...
https://doi.org/10.1176/appi.ps.202000362
Psychiatric Services (Washington, D.C.); Lu CY, Busch AB et. al.

May 11th, 2021 - High-deductible health plans (HDHPs) require substantial out-of-pocket spending for most services, although medications may be subject to traditional copayment arrangements. This study examined effects of HDHPs on medication out-of-pocket spending...

'Calcium Imbalance' Linked to Bipolar Severity
https://www.medscape.com/viewarticle/950877

May 10th, 2021 - Calcium homeostasis may play a role in bipolar disorder (BD) severity, with raised serum vitamin D and parathyroid hormone (PTH) levels linked to worse clinical outcomes and high psychological burden, new research suggests. After measuring serum P...

see more →

News  1,413 results

'Calcium Imbalance' Linked to Bipolar Severity
https://www.medscape.com/viewarticle/950877

May 10th, 2021 - Calcium homeostasis may play a role in bipolar disorder (BD) severity, with raised serum vitamin D and parathyroid hormone (PTH) levels linked to worse clinical outcomes and high psychological burden, new research suggests. After measuring serum P...

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness
https://www.medscape.com/viewarticle/950613

May 4th, 2021 - An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-co...

Heart Rate Variability a Biomarker of Bipolar Disorder Severity?
https://www.medscape.com/viewarticle/949989

Apr 25th, 2021 - Reduced heart rate variability (HRV) is associated with severity in patients with bipolar disorder (BD), in terms of both individual and overall measures of disease severity, new research suggests. In a study that included 53 adult patients with B...

Blood Tests Offer the Promise of Precision Psychiatry
https://www.medscape.com/viewarticle/949583

Apr 19th, 2021 - A panel of blood-based biomarkers can distinguish between depression and bipolar disorder, predict a person's future risk for these disorders, and inform more tailored medication choices, new research shows. Dr Alexander Niculescu "In terms of pre...

No More Excuses: Vaccine Trials Prove Clinical Trial Diversity Is Doable
https://www.medscape.com/viewarticle/945400

Feb 9th, 2021 - The increased representation of minority patients in the COVID vaccine trials puts the rest of medicine to shame. For decades there have been calls to make clinical trials more diverse, but the 2015-2019 Drug Trials Snapshots Summary Report by the...

see more →

Patient Education  47 results see all →